Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RL-007 in Cognitive Impairment Associated with Schizophrenia
2023-506570-12-01Phase 2Completed
- Sponsor
- Recognify Life Sciences
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in cognitive disorder (CD) and schizophrenia comparing RL-007 with Placebo (2 arms). Primary endpoint: MCCB neurocognitive composite score. Started May 2024; status: completed.
02
Drugs
inidascamine
03
Conditions
cognitive disorder (CD)schizophrenia
Beyond the preview
Go deeper on 2023-506570-12-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506570-12-01.